Autoimmune Encephalitis clinical trials at University of California Health
2 research studies open to eligible people
Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.
at UCSF
ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
open to eligible people ages 18 years and up
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
at UC Davis UC Irvine
Our lead scientists for Autoimmune Encephalitis research studies include Xiao-Tang Kong, MD Mustafa Ansari, MD.
Last updated: